A 2025 phase II trial of ziftomenib (menin inhibitor) + gilteritinib in NPM1/FLT3 co-mutated AML reported a 60% complete remission with hematologic recovery (CR/CRh) rate (Crews et al., 2023). This evidence concerns the gene MEN1 and acute myeloid leukemia.